Fluorocytosine (CAS 2022-85-7) is a cornerstone medication in the treatment of serious fungal infections. As an antifungal agent, it plays a critical role, particularly when used in combination therapies that are essential for managing severe systemic mycoses.

The effectiveness of Fluorocytosine stems from its unique mechanism of action. Once inside the fungal cell, it is converted into fluorouracil, a substance that disrupts essential protein synthesis and DNA replication. This biochemical conversion is key to its antifungal properties. While it can be used for chromomycosis, its most critical applications are in treating severe Candida infections and cryptococcosis, often in conjunction with Amphotericin B. This combination therapy approach is vital for achieving better clinical outcomes and preventing the development of resistance.

The molecular formula, C4H4FN3O, represents a compound with a significant therapeutic profile. Available as a white or off-white powder, it meets enterprise-level quality standards, including USP, BP, and EP, ensuring its reliability for pharmaceutical use. With an assay of ≥98%, it represents a high-quality active pharmaceutical ingredient (API).

For those in the pharmaceutical industry seeking this critical ingredient, understanding its applications and sourcing reliably is important. As a manufacturer and supplier of Fluorocytosine from China, we ensure that this vital antifungal agent is accessible, meeting the stringent purity and quality requirements necessary for effective treatment of challenging fungal infections.